What to know about TrumpRx: The White House’s new prescription drug platform

President Trump on Thursday unveiled TrumpRx.gov, a government-backed website aimed at offering Americans discounted prices on prescription medications. The launch represents a key component of his administration’s efforts to address healthcare affordability ahead of the midterm elections.

How TrumpRx Works

TrumpRx does not sell medications directly to patients. Instead, the platform acts as a central hub that directs consumers to pharmaceutical companies offering discounts on their own direct-to-consumer websites or provides discount coupons for use at participating pharmacies.

Patients can either print coupons or download them to a mobile wallet and present them at participating pharmacies, according to The Washington Times. For specialty medications, the site directs users to mail-order pharmacies.

Participating Companies and Drug Pricing

At launch, TrumpRx features medications from five companies: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer. Trump said 16 of the 17 largest pharmaceutical companies have signed agreements, with additional drugmakers joining in coming months.

Notable discounts include:

• Ozempic (diabetes): Starting at $199 per month, down from around $1,000
• Wegovy (obesity): Starting at $199 per month, down from around $1,350
• Zepbound (obesity): Starting at $299 per month, down from $1,086
• Januvia (diabetes): $100, reduced from $330
• Repatha (cholesterol): $239, reduced from $573

The Most Favored Nation Policy

TrumpRx stems from agreements between the Trump administration and pharmaceutical companies under “most favored nation” pricing policies that link U.S. drug prices to the lowest prices paid by other countries.

“Americans have long been paying the highest drug prices anywhere in the world,” Mr. Trump said at the launch event. “Under the agreements my administration has negotiated, the United States will pay the lowest price paid by any other country.”

In exchange, drugmakers received exemptions from certain tariffs and expedited product reviews.

Questions About Actual Savings

Health policy experts have raised questions about who will truly benefit from TrumpRx and whether savings are as significant as advertised.

Juliette Cubanski, deputy director of the program on Medicare Policy at KFF, told CNBC that TrumpRx “doesn’t seem like it is the only solution” for most Americans. “If they’re able to get a drug covered by their insurance at a relatively affordable copay, then there’s not a great upside to using the TrumpRx website.”

A key concern is that purchases through TrumpRx generally won’t count toward insurance deductibles or out-of-pocket maximums, meaning patients with insurance might ultimately pay less by using their coverage.

The announced price reductions are calculated against retail list prices, which, as CNBC reports, are often far higher than what private insurers and government programs actually pay after rebates and discounts.

Who Will Benefit Most?

Experts agree TrumpRx is most likely to help:

Uninsured patients: 27.2 million Americans are uninsured and must pay out of pocket for medications.

High-deductible plan members: Over 80 million Americans are enrolled in high-deductible health plans that require them to pay full list prices until their insurance coverage begins.

Patients needing drugs not widely covered: Ms. Cubanski noted TrumpRx has potential for expanding access to medications like obesity drugs, which many employers remain hesitant to cover.

Expert Reactions

Dr. Jeffrey Singer of the Cato Institute told The Washington Times that direct-to-consumer sales can lower prices by increasing competition. However, he warned that “a government-run platform isn’t necessary to achieve that goal” and that “federal involvement risks crowding out competition.”

Rena Conti, an associate professor at Boston University, said “TrumpRx might support access and affordability for a very small number of people.”

While TrumpRx represents an unprecedented government effort to facilitate direct-to-consumer drug purchases, its real-world impact remains uncertain. The platform may provide meaningful savings for uninsured patients and those with high-deductible plans, but for most Americans with traditional insurance coverage, existing benefits may still prove more economical over time.